135 related articles for article (PubMed ID: 15728853)
21. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.
Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A
Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946
[TBL] [Abstract][Full Text] [Related]
22. Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.
Zenchak JR; Palmateer B; Dorka N; Brown TM; Wagner LM; Medendorp WE; Petersen ED; Prakash M; Hochgeschwender U
J Neurosci Res; 2020 Mar; 98(3):458-468. PubMed ID: 29577367
[TBL] [Abstract][Full Text] [Related]
23. N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.
Crupi R; Impellizzeri D; Cordaro M; Siracusa R; Casili G; Evangelista M; Cuzzocrea S
Mol Neurobiol; 2018 Nov; 55(11):8455-8472. PubMed ID: 29552727
[TBL] [Abstract][Full Text] [Related]
24. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Suarez LM; Alberquilla S; García-Montes JR; Moratalla R
J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1/2-dependent mechanism.
Allen EN; Potdar S; Tapias V; Parmar M; Mizuno CS; Rimando A; Cavanaugh JE
J Nutr Biochem; 2018 Apr; 54():77-86. PubMed ID: 29268122
[TBL] [Abstract][Full Text] [Related]
26. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.
Maiti P; Manna J; Dunbar GL
Transl Neurodegener; 2017; 6():28. PubMed ID: 29090092
[TBL] [Abstract][Full Text] [Related]
27. Early Postnatal but Not Late Adult Neurogenesis Is Impaired in the Pitx3-Mutant Animal Model of Parkinson's Disease.
Brandt MD; Krüger-Gerlach D; Hermann A; Meyer AK; Kim KS; Storch A
Front Neurosci; 2017; 11():471. PubMed ID: 28883785
[TBL] [Abstract][Full Text] [Related]
28. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
[TBL] [Abstract][Full Text] [Related]
29. Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice.
Perruolo G; Viggiano D; Fiory F; Cassese A; Nigro C; Liotti A; Miele C; Beguinot F; Formisano P
Sci Rep; 2016 Jul; 6():29967. PubMed ID: 27426254
[TBL] [Abstract][Full Text] [Related]
30. RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer.
Ahlers KE; Chakravarti B; Fisher RA
AAPS J; 2016 May; 18(3):560-72. PubMed ID: 27002730
[TBL] [Abstract][Full Text] [Related]
31. Development and function of the midbrain dopamine system: what we know and what we need to.
Bissonette GB; Roesch MR
Genes Brain Behav; 2016 Jan; 15(1):62-73. PubMed ID: 26548362
[TBL] [Abstract][Full Text] [Related]
32. Monoamine neurotransmitter disorders--clinical advances and future perspectives.
Ng J; Papandreou A; Heales SJ; Kurian MA
Nat Rev Neurol; 2015 Oct; 11(10):567-84. PubMed ID: 26392380
[TBL] [Abstract][Full Text] [Related]
33. Lysosomes to combat Parkinson's disease.
Isacson O
Nat Neurosci; 2015 Jun; 18(6):792-3. PubMed ID: 26007211
[No Abstract] [Full Text] [Related]
34. Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease.
Laguna A; Schintu N; Nobre A; Alvarsson A; Volakakis N; Jacobsen JK; Gómez-Galán M; Sopova E; Joodmardi E; Yoshitake T; Deng Q; Kehr J; Ericson J; Svenningsson P; Shupliakov O; Perlmann T
Nat Neurosci; 2015 Jun; 18(6):826-35. PubMed ID: 25915474
[TBL] [Abstract][Full Text] [Related]
35. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Gellhaar S; Marcellino D; Abrams MB; Galter D
Genes Brain Behav; 2015 Mar; 14(3):260-70. PubMed ID: 25752644
[TBL] [Abstract][Full Text] [Related]
36. Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
Lim SAO; Xia R; Ding Y; Won L; Ray WJ; Hitchcock SA; McGehee DS; Kang UJ
Neurobiol Dis; 2015 Apr; 76():67-76. PubMed ID: 25661301
[TBL] [Abstract][Full Text] [Related]
37. Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra.
Bifsha P; Yang J; Fisher RA; Drouin J
PLoS Genet; 2014 Dec; 10(12):e1004863. PubMed ID: 25501001
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Masoud ST; Vecchio LM; Bergeron Y; Hossain MM; Nguyen LT; Bermejo MK; Kile B; Sotnikova TD; Siesser WB; Gainetdinov RR; Wightman RM; Caron MG; Richardson JR; Miller GW; Ramsey AJ; Cyr M; Salahpour A
Neurobiol Dis; 2015 Feb; 74():66-75. PubMed ID: 25447236
[TBL] [Abstract][Full Text] [Related]
39. Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.
Lu W; Karuppagounder SS; Springer DA; Allen MD; Zheng L; Chao B; Zhang Y; Dawson VL; Dawson TM; Lenardo M
Nat Commun; 2014 Sep; 5():4930. PubMed ID: 25222142
[TBL] [Abstract][Full Text] [Related]
40. Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice.
Liu Y; Yuan YH; Sun JD; Li J; Li ZP; Chen NH
F1000Res; 2014; 3():68. PubMed ID: 25210616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
